• Reduce text

    Reduce text
  • Restore text size

    Restore text size
  • Increase the text

    Increase the text
  • Print


POSITIVe: a new multidisciplinary scientific network  on the interindividual variation in response to consumption of plant food bioactives

POSITIVe gathers experts from 30 European countries for 4 years. They will cooperate to better understand the factors associated with human variability and its effects on the responsiveness to the intake of plant food bioactive compounds. This action is coordinated by Dr Christine Morand (INRA, Human Nutrition Unit, France) and Dr Francisco Tomas-Barberan (CEBAS-CSIC, Spain) is vice-coordinator.

Updated on 07/06/2017
Published on 03/03/2015

Cardiovascular and metabolic diseases can be prevented, delayed or reduced by improving our eating habits. Increasing the consumption of plant foods rich in a range of compounds with potential beneficial effects (‘bioactive compounds’) is an important strategy to fight these chronicle diseases. However, the translation of many promising preclinical results into human clinical trials has so far proven challenging mostly due to the large heterogeneity in individuals’ responsiveness to the intake of these compounds.

POSITIVe will specifically address this issue by tackling:

1) the variability in human bioavailability and capacity to metabolize these compounds (working group, WG1);

2) the variability in the response (bioactivity) of humans to the intake of these compounds (WG2) and

3) the translation of the results from WG1 and WG2 into applications relevant to the scientific community, food industry, public health regulatory authorities, health care professionals and the general public (consumers).

The Action will also work and cooperate in the dissemination of results and information provided by the WGs (Focusing group, FG) and the training of young scientists (Short Scientific Missions, STMs). All these efforts will lead to a better understanding of the beneficial effects of plant bioactive compounds and their application against human cardiovascular and metabolic diseases and will position European researchers at the leadership of this field. It will also provide new scientific knowledge to regulatory authorities for specific dietary recommendations directed to population groups and to the European food industry for the development of new functional personalized foods.

Scientific contact(s):

Find out more

More on POSITIVe Action: http://www6.inra.fr/cost-positive